Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00054147" target="_blank" >RIV/00216224:14110/11:00054147 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/11:10582 RIV/65269705:_____/11:#0001341
Result on the web
<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >http://dx.doi.org/10.1097/MEG.0b013e32834b326b</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >10.1097/MEG.0b013e32834b326b</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe
Original language description
Objective Assess the safety and efficacy of 24 or 48 weeks of treatment with peginterferon alpha-2a (40KD) plus ribavirin in treatment-naive patients with chronic hepatitis C. Methods All patients in this open-label multinational study were assigned at the investigator's discretion to receive peginterferon alpha-2a (40KD) 180 mu g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon alpha-2a (40KD) 180 mu g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. Results A total of 789 treatment-naive patients were enroled, of whom 91% (138 of 152) of nongenotype 1 patients and 77% (490 of 637) of genotype 1 patients completed 24 and 48 weeks of treatment, respectively. The overall SVR rate was 58% (459 of 789), and was 70 and 55% in nongenotype 1 and genotype 1 patients, res
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FN - Epidemiology, infection diseases and clinical immunology
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Gastroenterology and Hepatology
ISSN
0954-691X
e-ISSN
—
Volume of the periodical
23
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
1004-1010
UT code for WoS article
000295831900006
EID of the result in the Scopus database
—